Kymera Therapeutics (KYMR) Enterprise Value (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Enterprise Value data on file, last reported at -$650.9 million in Q1 2026.

• On a quarterly basis, Enterprise Value fell 40.54% year-over-year to -$650.9 million in Q1 2026; TTM through Mar 2026 was -$650.9 million, a 40.54% decrease from a year earlier, with the FY2025 full-year figure at -$848.3 million, down 73.56% from the prior year.
• Enterprise Value for Q1 2026 stood at -$650.9 million, up from -$848.3 million in the prior quarter.
• Over the last five years, Enterprise Value for KYMR reached as high as -$33.7 million in Q1 2022 and fell as low as -$848.3 million in Q4 2025.
• Historically, Enterprise Value has averaged -$452.9 million across 5 years, with a median of -$481.9 million in 2022.
• Across the five-year window, Enterprise Value surged 89.89% in 2022 and slumped 1076.52% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$407.2 million in 2022, then grew by 7.93% to -$374.9 million in 2023, then slumped by 30.37% to -$488.7 million in 2024, then plunged by 73.56% to -$848.3 million in 2025, then gained by 23.26% to -$650.9 million in 2026.
• Per Business Quant data, the three most recent Enterprise Value figures were -$650.9 million in Q1 2026, -$848.3 million in Q4 2025, and -$505.7 million in Q3 2025.